Nine-year-old Utah telehealth firm offering compounded and brand GLP-1s in all fifty states.
Belle Health — FDA warning letter, February 2026. Addressed to Belle Health LLC dba Belle, and public in FDA’s warning-letter database.
- SemaglutideFrom $119/mo
- TirzepatideFrom $175/mo
Assume we may earn a commission, at no cost to you. Partners we work with carry a small, fixed edge in where they are listed; the scores themselves are not adjusted.
- Semaglutide
- From $119/mo (compounded)
- Tirzepatide
- From $175/mo (compounded)
- Coverage
- All 50 states
- Brand-name
- Yes
The scorecard
Belle Health scored on our six published factors. See the methodology.
What we like
- Offers brand Wegovy (from $1,400/mo) and brand Zepbound (from $1,999/mo) alongside the compounded lines, so a switch to an FDA-approved product does not mean changing provider
- Compounded prices are published before intake: from $119 a month for semaglutide and from $175 a month for tirzepatide
- Weekly registered-dietitian sessions are included in the monthly price at no extra charge
- Trading since 2017, which is unusually long for this segment
- The site states plainly that 'Compounded medications are not evaluated or approved by the FDA' rather than burying the caveat
The caveats
- FDA issued a warning letter to Belle Health LLC dba Belle in February 2026; it is public in FDA's warning-letter database
- Compounded semaglutide and tirzepatide are not FDA-approved and are not reviewed by the FDA for safety, effectiveness or quality
- Both compounded prices are 'from' prices, so the figure you are quoted after intake may be higher than the one advertised
- The pharmacy partners named in the Terms have been swapped out entirely, and two of the current four have publicly stepped back from GLP-1 compounding
- No refunds on prescription or compounded products once shipped, and no telephone support is published
The verdict
Best for: Someone who wants a compounded starting price at the low end of the market with the option to switch to brand Wegovy or Zepbound on the same account.
Ranked #234 of 548 providers we have reviewed — for comparison, read the CoreAge Rx review, ranked #1. In the ranking it sits between System Labs at #233, 65/100 above and Bayan Health at #235, 67/100 below, with the ARSYNL Rx write-up the next one down.
If that review leaves you undecided, the 7 programs we rank against Belle Health are graded on the same six factors and listed in score order. This review sits inside a bigger picture: the complete ranking puts this review in context against every program we track. We have also compared it head to head: CoreAge Rx vs Belle Health goes to CoreAge Rx, 94/100 to 67/100.
Compare Belle Health
Compare with other providers
The closest reviews to Belle Health by Verdict Score — the realistic shortlist if you are weighing this one up.
- #203TelePeptide— TelePeptide is a LegitScript-certified US direct-pay telehealth practice offering physician-supervised compounded GLP-1 therapy — semaglutide and tirzepatide — in injectable and oral dissolvable tablet…69/100
- #204The Aesthetic Concierge— The Aesthetic Concierge is a physician-led US telehealth practice offering GLP-1 medical weight loss.69/100
- #205WePeptideRx— WePeptideRx is a provider-guided telehealth platform offering compounded semaglutide and tirzepatide alongside a deep menu of peptide, hormone, hair, and sexual-wellness programs.69/100
- #206Collective— Medication figures at the low end of everything we rule on, on top of a mandatory annual membership the headline never mentions.66/100
- #207NEUVE Health— A wide catalog and a clean interface around one unanswered question: whether the monthly figure includes the medicine.68/100
- #208The Edit— Introductory compounded care at $200 semaglutide or $300 tirzepatide, followed by higher recurring monthly prices.68/100
Pricing, states and verification reflect Belle Health's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on Belle Health's site. Not medical advice; see our disclosure.